DNA samples for both GWAS and verification analyses were from tamoxifen-treated patients with breast cancer recruited for our previous study of correlations between CYP2D6 genotype and plasma concentrations of the drug and its 14 metabolites [27]: All patient CYP2D6 genotype data and concentration measurements were derived from that study. The gene discussed is CYP2D6; the disease is breast cancer.